Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma

Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Won-Seop, Kim, Dae-Hyeok, Shin, Sung-Hee, Woo, Seoung-Il, Kwan, Jun, Park, Keum-Soo, Park, Sang-Don, Yi, Hyeon-Gyu, Jeon, Sang-Hoon
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017698/
https://www.ncbi.nlm.nih.gov/pubmed/21155055
http://dx.doi.org/10.3349/ymj.2011.52.1.196
_version_ 1782195935497945088
author Lee, Won-Seop
Kim, Dae-Hyeok
Shin, Sung-Hee
Woo, Seoung-Il
Kwan, Jun
Park, Keum-Soo
Park, Sang-Don
Yi, Hyeon-Gyu
Jeon, Sang-Hoon
author_facet Lee, Won-Seop
Kim, Dae-Hyeok
Shin, Sung-Hee
Woo, Seoung-Il
Kwan, Jun
Park, Keum-Soo
Park, Sang-Don
Yi, Hyeon-Gyu
Jeon, Sang-Hoon
author_sort Lee, Won-Seop
collection PubMed
description Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of complete atrioventricular block while receiving bortezomib. We immediately stopped bortezomib, and after inserting a permanent VDD pacemaker, the patients' symptoms disappeared.
format Text
id pubmed-3017698
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-30176982011-01-10 Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma Lee, Won-Seop Kim, Dae-Hyeok Shin, Sung-Hee Woo, Seoung-Il Kwan, Jun Park, Keum-Soo Park, Sang-Don Yi, Hyeon-Gyu Jeon, Sang-Hoon Yonsei Med J Case Report Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of complete atrioventricular block while receiving bortezomib. We immediately stopped bortezomib, and after inserting a permanent VDD pacemaker, the patients' symptoms disappeared. Yonsei University College of Medicine 2011-01-01 2010-11-30 /pmc/articles/PMC3017698/ /pubmed/21155055 http://dx.doi.org/10.3349/ymj.2011.52.1.196 Text en © Copyright: Yonsei University College of Medicine 2011 http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Lee, Won-Seop
Kim, Dae-Hyeok
Shin, Sung-Hee
Woo, Seoung-Il
Kwan, Jun
Park, Keum-Soo
Park, Sang-Don
Yi, Hyeon-Gyu
Jeon, Sang-Hoon
Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
title Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
title_full Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
title_fullStr Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
title_full_unstemmed Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
title_short Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
title_sort complete atrioventricular block secondary to bortezomib use in multiple myeloma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017698/
https://www.ncbi.nlm.nih.gov/pubmed/21155055
http://dx.doi.org/10.3349/ymj.2011.52.1.196
work_keys_str_mv AT leewonseop completeatrioventricularblocksecondarytobortezomibuseinmultiplemyeloma
AT kimdaehyeok completeatrioventricularblocksecondarytobortezomibuseinmultiplemyeloma
AT shinsunghee completeatrioventricularblocksecondarytobortezomibuseinmultiplemyeloma
AT wooseoungil completeatrioventricularblocksecondarytobortezomibuseinmultiplemyeloma
AT kwanjun completeatrioventricularblocksecondarytobortezomibuseinmultiplemyeloma
AT parkkeumsoo completeatrioventricularblocksecondarytobortezomibuseinmultiplemyeloma
AT parksangdon completeatrioventricularblocksecondarytobortezomibuseinmultiplemyeloma
AT yihyeongyu completeatrioventricularblocksecondarytobortezomibuseinmultiplemyeloma
AT jeonsanghoon completeatrioventricularblocksecondarytobortezomibuseinmultiplemyeloma